• Lundbeck disclosed Phase Ib results for Lu AF28996 in advanced Parkinson’s disease, with data being presented at MDS 2026.
• The open-label study showed the oral dopamine agonist prodrug was generally tolerable, with mostly mild side effects.
• Patients showed signs of improved motor control, including less time with poor symptom control and less dyskinesia.
• Development moved into Phase II, with the first patient randomized in the DARE2 placebo-controlled trial targeting motor fluctuations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief via Cision (Ref. ID: 202610060200BITN____UKPR__EN_20261002-BIT-8633-0) on October 06, 2026, and is solely responsible for the information contained therein.